Drug developers at SfN 2026

Nov 14–18, 2026 Washington, DC ~21k attendees Website

47 drug developers are at SfN 2026 — 70 presentations on the program. Most represented: Johnson & Johnson (5 on the program), Sanofi (5 on the program), AbbVie (3 on the program). 14 of them have their own page in this guide. As of Oct 9, 2026.

All 1,867 organizations at SfN 2026 →

Showing 1–12 of 47 organizations

Organization	SfN 2026 Attendance
Johnson & Johnson San Diego, CA
jnj.com Drug developers Pharmaceutical and healthcare company conducting research and developing medicines, including in neuroscience.	Poster Sat Nov 14 1–5pm Part of Session PSTR007: Network Interactions: Other Bridging rodent and human biology with an optimized iPSC triculture HD-MEA model to interrogate network excitability alterations in neuropsychiatric disorders WCC Halls A-C · Board T22 Poster Sun Nov 15 8am–noon Part of Session PSTR046: Oligodendrocytes: Disease Mechanisms A Bipolar Patient-Derived Pipeline from Fibroblast Metabolism to Oligodendrocyte Phenotyping WCC Halls A-C · Board Q4 Poster Sun Nov 15 1–5pm Part of Session PSTR117: Decoding Large-Scale Neural Dynamics: Models, States, and Whole-Brain Population Computation Interpretable, Data‑Driven MRI Quality Control Using Deep Learning WCC Halls A-C · Board KK59 Poster Mon Nov 16 8am–noon Part of Session PSTR130: Neural-Immune Signaling in Neuropsychiatric and Neurodevelopmental Disorders Microglial cell states associated with psychiatric disorders WCC Halls A-C · Board V5 Poster Wed Nov 18 8am–noon Part of Session LBP075: J.05. Biomarker, Drug Discovery, and Experimental Therapeutics Characterization of Metrics Quantifying Neural Dynamics Across Large-scale Psychosis-Spectrum Cohorts WCC Halls A-C · Board B58
Sanofi Cambridge, MA
sanofi.com Drug developers Pharmaceutical company conducting research and developing medicines, including neuroscience research.	Poster Sat Nov 14 1–5pm Part of Session PSTR014: ALS and Motor Neuron Diseases: In Vitro Studies TDP-43 loss-of-function in astrocytes drives cell-type-specific cryptic exon dysregulation, and is amplified by NMD inhibition WCC Halls A-C · Board X5 Poster Sun Nov 15 8am–noon Part of Session LBP002: C.02. Alzheimer's Disease and Other Dementias The EPND Consortium: Neuroinflammatory and Astrogliosis Signatures Distinguish Disease-Specific and Shared Molecular Pathways Across Neurodegenerative Diseases in CSF Proteomics WCC Halls A-C · Board B70 Poster Mon Nov 16 1–5pm Part of Session PSTR192: Sleep Regulation: Anatomy, Pharmacology, Behavior Orexin/ataxin-3 model mice show sleep and neurochemical phenotypes reminiscent of narcolepsy type I (NT1) WCC Halls A-C · Board FF2 Poster Tue Nov 17 8am–noon Part of Session PSTR224: Stroke, Ischemia, and Vascular Injury: Mechanistic Studies Characterizing Acute Neuroinflammation and Microglial Response Following Ischemic Stroke WCC Halls A-C · Board X30 Poster Wed Nov 18 8am–noon Part of Session PSTR309: ALS and Motor Neuron Diseases: Human Genetics, Cellular Mechanisms, and Animal Models TDP-43 Q331K overexpression leads to perturbed metabolic and circadian function in a mouse model WCC Halls A-C · Board Y19
AbbVie Cambridge, MA
abbvie.com Drug developers Pharmaceutical company conducting neuroscience research, including work in movement disorders.	Poster Sat Nov 14 1–5pm Part of Session PSTR038: Neurodegenerative Diseases (AD, PD, MS, Stroke) Development of a Unique Mouse Model of In Vivo Tau Propagation for Evaluating Efficacy of Anti Tau Antibodies WCC Halls A-C · Board KK43 Poster Sun Nov 15 1–5pm Part of Session PSTR090: Parkinson's Disease: Glias and Immune Actions Examining the role of neuroinflammation in the spread of alpha-synuclein pathology in a Parkinson's disease mouse model WCC Halls A-C · Board U7 Poster Mon Nov 16 1–5pm Part of Session PSTR171: Parkinson's Disease: Animal Models Investigating the propagation of alpha synuclein aggregation following pre-formed fibril injections in human alpha-synuclein expressing mice WCC Halls A-C · Board Q2
TT Tenvie Therapeutics Brisbane, CA
Drug developers Biotechnology company developing medicines for neurological and psychiatric disorders.	Poster Mon Nov 16 1–5pm Part of Session PSTR173: Neuroprotective Mechanisms: Preclinical A Potent Allosteric SARM1 Inhibitor Protects Against Axonal Degeneration and Advances to Clinical Evaluation WCC Halls A-C · Board U1 Poster Mon Nov 16 1–5pm Part of Session PSTR173: Neuroprotective Mechanisms: Preclinical Structural and Mechanistic Characterization of Allosteric SARM1 Inhibition Supports Clinical Translation for Neuroprotection WCC Halls A-C · Board U7 Poster Wed Nov 18 1–5pm Part of Session PSTR370: Control of Thirst, Appetite, and Energy Balance CNS-penetrant NLRP3 inhibitor achieves durable weight loss and reverses hypothalamic inflammation in diet-induced obesity WCC Halls A-C · Board HH4
S Sironax Beijing, China
Drug developers Biotechnology company developing medicines for neurodegenerative diseases.	Poster Sun Nov 15 1–5pm Part of Session PSTR091: ALS and Motor Neuron Diseases: Therapeutics Neuroprotective Effects of SIR2501, an Allosteric SARM1 Inhibitor, in Preclinical Studies of ALS, Glaucoma, and Ischemic Stroke WCC Halls A-C · Board U20 Poster Sun Nov 15 1–5pm Part of Session PSTR091: ALS and Motor Neuron Diseases: Therapeutics SIR2501, a Novel SARM1 Inhibitor, Demonstrates Favorable Safety and Early Evidence of Biological Activity in Patients With Amyotrophic Lateral Sclerosis WCC Halls A-C · Board U21 Poster Wed Nov 18 1–5pm Part of Session PSTR357: Peripheral Nerve Damage, Neuropathic Pain, and Repair SIR2501, a novel SARM1 Inhibitor, Demonstrates Favorable Safety, Predictable Pharmacokinetics, and Early Signals of Protection Against Chemotherapy-Induced Peripheral Neuropathy WCC Halls A-C · Board Z4
Alkermes Waltham, MA
alkermes.com Drug developers Biopharmaceutical company developing medicines for neurologic and psychiatric disorders.	Poster Sun Nov 15 8am–noon Part of Session PSTR061: Systems Behavior Antipsychotics with different mechanisms of action display distinct neural activation profiles in the striatum WCC Halls A-C · Board CC20 Poster Sun Nov 15 1–5pm Part of Session PSTR085: Anticonvulsant and Antiepileptic Therapies Employing Multi-Electrode Array (MEA) to Investigate Effects of Anti-Epileptic Drugs on Neuronal Network Activity WCC Halls A-C · Board M4
BioAge Labs Emeryville, CA
bioagelabs.com Drug developers Develops medicines targeting biology associated with aging and age-related diseases.	Poster Mon Nov 16 1–5pm Part of Session PSTR169: Pharmacological and Non-Pharmacological Interventions for Brain Aging Oral NLRP3 Inhibition Improves Behavioral Phenotypes Associated with Brain Aging in Mice WCC Halls A-C · Board L8 Poster Wed Nov 18 1–5pm Part of Session PSTR350: Alzheimer's Disease:?Metabolomics, Proteomics, and Multi-Omics Longitudinal Plasma Proteomic Profiling over Decades Reveals Sequential Biological Changes Preceding Alzheimer’s Disease, and an Investigational NLRP3 Inflammasome Inhibitor Shifts The Risk Signatures Toward Protection WCC Halls A-C · Board U13
Merck & Co. Cambridge, MA
merck.com Drug developers Pharmaceutical company developing medicines and conducting neuroscience research.	Talk Sun Nov 15 10:15–10:30am Part of Session NANO08: Neural-Immune Signaling in Alzheimer's Disease Plaque-associated oligodendrocyte proteostatic failure is linked to myelin loss in Alzheimer’s disease WCC Rm 145 Poster Tue Nov 17 1–5pm Part of Session PSTR270: Nociceptors, Thermoreceptors, and Pruriceptors Integration of Human Peripheral Ganglia Spatial Transcriptomics Data Identifies Dorsal Root Ganglion-enriched Targets for Pain Therapeutics WCC Halls A-C · Board BB1
Oligomerix Bronx, NY
oligomerix.com Drug developers Biotechnology company developing therapies for neurodegenerative diseases, including Alzheimer’s disease.	Poster Sun Nov 15 8am–noon Part of Session LBP002: C.02. Alzheimer's Disease and Other Dementias Treatment with OLX-07010 inhibited the induction and spread of tau pathology by AD tau seeded into humanized tau mice WCC Halls A-C · Board B60 Poster Mon Nov 16 8am–noon Part of Session PSTR127: Alzheimer's Disease Therapeutic Strategies: Tau Clinically relevant blood biomarkers for tau and inflammation are reduced by treatment with OLX-07010 in P301L Tau x APPSwe mice WCC Halls A-C · Board T31
AP Axoltis Pharma Lyon, France
Drug developers Develops neuroprotective therapies for neurological disorders.	Poster Sun Nov 15 1–5pm Part of Session PSTR091: ALS and Motor Neuron Diseases: Therapeutics SEALS: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Evaluating Efficacy And Safety Of NX210c In Amyotrophic Lateral Sclerosis (ALS) Patients WCC Halls A-C · Board U11 Poster Sun Nov 15 1–5pm Part of Session PSTR091: ALS and Motor Neuron Diseases: Therapeutics NX210c, an innovative peptide with neurovascular and peripheral effect in ALS WCC Halls A-C · Board U17
Abbott Plano, TX
abbott.com Drug developers Healthcare company developing pharmaceuticals, medical devices, diagnostics and nutrition products.	Poster Sun Nov 15 1–5pm Part of Session PSTR118: Electrical A Hierarchical Control Model for Closed-Loop DBS in Parkinson's Disease:Scoping the Scientific and Computational Requirements WCC Halls A-C · Board KK63 Poster Wed Nov 18 1–5pm Part of Session LBP086: I.08. Learning and Memory Effects of Early Life Choline and Betaine Supplementation on Cognitive Performance in Mice WCC Halls A-C · Board C7
REGENXBIO Rockville, MD
regenxbio.com Drug developers Clinical-stage biotechnology company developing AAV gene therapies, based in Rockville, Maryland.	Poster Tue Nov 17 1–5pm Part of Session PSTR266: Other Neuromuscular Diseases An AAV-expressed microdystrophin with an extended C-terminal domain rescues neuromuscular junction deficits in a mouse model of Duchenne Muscular Dystrophy WCC Halls A-C · Board Y14 Poster Wed Nov 18 1–5pm Part of Session PSTR382: Drug Delivery A novel liver de-targeted blood-brain barrier penetrant AAV capsid robustly transduces the CNS while minimizing transduction of peripheral tissues WCC Halls A-C · Board LL59

Instantly find 20 buyers from drug developers

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with the Society for Neuroscience. Organization details are derived from SfN’s published exhibitor list, its Neuroscience Meeting Planner and each organization’s own website. Submit a correction

Instantly find 20 buyers from drug developers

Browse SfN 2026 by